Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q1 2023 Earnings Presentation

42 slides from Day One Biopharmaceuticals's earnings presentation, May 1, 2023

  1. Slide 1: Targeted Therapies for People of All Ages

    Day One Biopharmaceuticals Day One Biopharmaceuticals Targeted Therapies for People of All Ages May 2023

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Cancer Drug Development for People of All Ages

    Cancer Drug Development for People of All Ages Growing Portfolio and Runway Beyond Clinical Milestones Tovorafenib (DAY101) Lead Program Mission That Creates Value Day One’s mission is to help children with cancer, from day one and every day after Develop medicines for genomically-defined cancers Es

  4. Slide 4: Our Pipeline

    Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Recent & Anticipated Milestones Tovorafenib (DAY101) Type II Pan-RAF Inhibitor Relapsed pLGG Frontline pLGG RAF-altered solid tumors2 (monotherapy) Pimasertib MEK 1/2 Inhibitor MAPK-altered solid tumors3 (Combo w/tovorafenib) Our Pipel

  5. Slide 5: Tovorafenib (DAY101) Type II Pan-RAF Inhibitor

    Day One Biopharmaceuticals Tovorafenib (DAY101) Type II Pan-RAF Inhibitor

  6. Slide 6: Pediatric Low-Grade Gliomas (pLGG)

    Pediatric Low-Grade Gliomas (pLGG) Day One Biopharmaceuticals Despite being the most common brain tumor in children, there are no approved agents and no standard-of-care for the majority of patients with relapsed/progressive disease1,2 ~70% of patients will require systemic therapy Patients have a h

  7. Slide 7: Tovorafenib (DAY101) Inhibits Both BRAF Fusions and BRAF V600 Mutations

    Tovorafenib (DAY101) Inhibits Both BRAF Fusions and BRAF V600 Mutations Day One Biopharmaceuticals Tovorafenib (DAY101) is an investigational, oral, selective, CNS-penetrant, type II pan-RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by bot

  8. Slide 8: The Current pLGG Treatment Paradigm

    The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor Day One Biopharmaceuticals Source: Physician Interviews, Bandopadhayay et al. Pediatric Blood Cancer. 2014; Sievert and Fischer. J Child Neurol. 2009; ClearView Analysis. GTR: Gross Total Resection 1Molec

  9. Slide 9: Pivotal Phase Trial of Tovorafenib in Relapsed or Progressive pLGG (FIREFLY-1)

    Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) in Relapsed or Progressive pLGG (FIREFLY-1) Day One Biopharmaceuticals Primary endpoint: ORR based on RANO-HGG criteria, assessed by blinded independent central review Secondary endpoints: ORR by RAPNO criteria; PFS; safety Exploratory analys

  10. Slide 10: FIREFLY-1 Baseline Patient Characteristics

    FIREFLY-1 Baseline Patient Characteristics Day One Biopharmaceuticals Characteristic Topline Data Arm 1 (N=77) Median age, years (range) 8 (2-21) BRAF alteration, n (%) BRAF V600E BRAF Fusion† 13 (17) 64 (83) Median number of lines of prior therapy (range) 3 (1-9) Prior MAPK pathway targeted therapy

  11. Slide 11: Topline Data from Ongoing Pivotal Phase FIREFLY-1 Trial

    Topline Data from Ongoing Pivotal Phase 2 FIREFLY-1 Trial Day One Biopharmaceuticals Sep 28, 2022 data cutoff. CR, complete response. PR, partial response. SD, stable disease. The primary endpoint of the FIREFLY-1 trial is overall response rate (ORR) by Response Assessment for Neuro-Oncology-High Gr

  12. Slide 12: Incidence and Prevalence of BRAF-altered pLGG in the U.S.

    ~26,000 Estimated Prevalence Incidence and Prevalence of BRAF-altered pLGG in the U.S. Day One Biopharmaceuticals 1. US Census; 2 CBTRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis; 3 SEER US complete prevalence counts of patients aged under 25 with Brain and Other Nervous Systems t

  13. Slide 13: FIREFLY-2/LOGGIC Pivotal Phase Trial in Newly Diagnosed pLGG

    Day One Biopharmaceuticals FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Newly Diagnosed pLGG

  14. Slide 14: FIREFLY-2/LOGGIC Pivotal Phase Trial of Tovorafenib in Newly Diagnosed pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Newly Diagnosed pLGG Day One Biopharmaceuticals Primary endpoint: ORR based on RANO-LGG criteria, assessed by blinded independent central review1 The ORR primary analysis is expected to occur ~12 months after the last patient randomiz

  15. Slide 15: FIREFLY-2/LOGGIC: Collaboration and Sites

    FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG Day One Biopharmaceuticals Collaboration between Day One and the LOGGIC consortium, internationally recognized experts in pLGG research Coupled with the LOGGIC-CORE molecular diagnostic program Worked jointly on

  16. Slide 16: Our Pipeline

    Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Recent & Anticipated Milestones Tovorafenib (DAY101) Type II Pan-RAF Inhibitor Relapsed pLGG Frontline pLGG RAF-altered solid tumors2 (monotherapy) Pimasertib MEK 1/2 Inhibitor MAPK-altered solid tumors3 (Combo w/tovorafenib) Our Pipel

  17. Slide 17: Phase Study of Monotherapy Tovorafenib in Solid Tumors (FIRELIGHT-1)

    Phase 2 Study of Monotherapy Tovorafenib (DAY101) in Solid Tumors (FIRELIGHT-1) Day One Biopharmaceuticals Abbreviations: ORR, objective response rate; QW, once weekly ; PO, by mouth; BRAF, B-Raf proto-oncogene. Umbrella master study – DAY101-102 (main protocol) DAY101 and MAPK pathway aberration, S

  18. Slide 18: Clinical Activity of Tovorafenib in BRAF Fusion Melanoma

    Day One Biopharmaceuticals Preliminary Clinical Activity of Tovorafenib (DAY101) Monotherapy in BRAF Fusion Melanoma Parameter Description/outcome Stage at diagnosis III EGOC status 0 Prior therapies Multiple lymphadenectomies and skin lesion excision surgery Pembrolizumab (11 weeks): Best response:

  19. Slide 19: Clinical Activity of Tovorafenib in BRAF Fusion Melanoma

    Day One Biopharmaceuticals Preliminary Clinical Activity of Tovorafenib (DAY101) Monotherapy in BRAF Fusion Melanoma Parameter Description/outcome Stage at diagnosis Unknown EGOC status 1 Prior therapies Radiation Nivolumab (12 mo, adjuvant setting): No best response, disease resected Nivolumab + ip

  20. Slide 20: Clinical Activity of Tovorafenib in BRAF Fusion Melanoma

    Day One Biopharmaceuticals Preliminary Clinical Activity of Tovorafenib (DAY101) Monotherapy in BRAF Fusion Melanoma Parameter Description/outcome Stage at diagnosis II EGOC status 0 Prior therapies Radiation Pembrolizumab (2 mo): Best response: SD Tovorafenib treatment to date in FL-1 102a (melanom

  21. Slide 21: Activity of Tovorafenib in SNX8:BRAF Fusion Spindle Cell Sarcoma

    Activity of Tovorafenib (DAY101) in SNX8:BRAF Fusion Spindle Cell Sarcoma Day One Biopharmaceuticals A male child spindle cell sarcoma, 5-years of age at diagnosis Data cut off: September 30, 2021 Months -30 -24 -18 -12 -6 0 6 Diagnosis BRAF fusion (FISH) CR PD CR Gemcitabine, docetaxel Proton radio

  22. Slide 22: Scientific Rationale for Combining Tovorafenib with Additional MAPK Pathway Inhibitors

    Strong Scientific Rationale for Combining Tovorafenib (DAY101) with Additional MAPK Pathway Inhibitors Day One Biopharmaceuticals Type II RAFi + MEKi Type II RAFi + MEKi Type II RAFi + SHP2i MEKi or Type II RAFi + SHP2i MEKi or KRAS - G12Ci or Potential combinations BRAF non-V600 BRAF or CRAF fusion

  23. Slide 23: Pimasertib MEK1/2 Inhibitor

    Day One Biopharmaceuticals Pimasertib MEK1/2 Inhibitor

  24. Slide 24: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor

    Pimasertib: Investigational Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors Day One Biopharmaceuticals Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 Extensive non-clini

  25. Slide 25: Vertical MAPK Pathway Inhibition with Tovorafenib and Pimasertib

    Vertical MAPK Pathway Inhibition with Tovorafenib (DAY101) and Pimasertib May Unlock Potential Synergy for Adult Solid Tumors Day One Biopharmaceuticals Pan-RAFi + MEKi is synergistic in BRAF fusion melanoma PDX model ex vivo (internal data) Sensitivity of KRAS Q61 mutant cells to pimasertib is enha

  26. Slide 26: Tovorafenib / Pimasertib Combination to be Evaluated in Solid Tumors

    Tovorafenib (DAY101) / Pimasertib Combination to be Evaluated in Solid Tumors (FIRELIGHT-1) Day One Biopharmaceuticals Abbreviations: BOIN, Bayesian Optimal Interval Design; BRAF, B-Raf proto-oncogene, serine/threonine kinase; MAPK, mitogen-activated protein kinase; NRAS, neuroblastoma rat sarcoma v

  27. Slide 27: Summary

    Day One Biopharmaceuticals Summary

  28. Slide 28: Financial Summary: DAWN

    Financial Summary: DAWN Day One Biopharmaceuticals $ Millions Three Months Ended 3/31/23 Three Months Ended 3/31/22 R&D Expense $27.8 $15.0 G&A Expense $18.0 $12.7 Net Loss $42.4 $27.7 FIREFLY-1: Pivotal Phase 2 clinical trial of tovorafenib (DAY101) Pre-NDA meeting held on April 19, 2023 Remain in

  29. Slide 29: Next Steps

    Next Steps Day One Biopharmaceuticals FIREFLY-1 Pre-NDA meeting held on April 19, 2023 Remain in position to initiate the NDA submission in Q2 2023 Presentation of new clinical data in oral presentation at ASCO conference FIREFLY-2 Advance tovorafenib as a front-line therapy for patients newly diagn

  30. Slide 30: Appendix

    Appendix Day One Biopharmaceuticals

  31. Slide 31: FIREFLY-1 Baseline Characteristics

    FIREFLY-1 Baseline Characteristics Day One Biopharmaceuticals Characteristic Arm 1 (N=25) Median age, years (range) 8 (3-18) Sex, n (%) Male Female 13 (52) 12 (48) Race, n (%) Black or African American Asian White Other* 1 (4) 2 (8) 15 (60) 7 (28) Karnofsky/Lansky performance status, n (%) 50-70 80-

  32. Slide 32: Tumor Response to Tovorafenib for RANO-HGG Evaluable Patients

    Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-HGG Evaluable Lesions (n=22)* Day One Biopharmaceuticals Response (IRC) RANO-HGG Evaluable N=22* ORR (95% CI) 64% (41-83) BRAF fusion (n=20) 60% BRAF V600E (n=2) 100% CBR# 91% Best overall response PR (13/22) 59% uPR (1/22) 5% SD (6/2

  33. Slide 33: Duration of Tovorafenib Therapy

    Duration of Tovorafenib (DAY101) Therapy For All Patients with RANO-HGG Evaluable Lesions (n=22) Day One Biopharmaceuticals Apr 14, 2022 data cutoff. 17/22 patients remain on therapy All responders remain on treatment

  34. Slide 34: Individual Patient Tumor Change From Baseline

    Individual Patient Tumor Change From Baseline (n=22 RANO-HGG Evaluable By Blinded Independent Central Review) Day One Biopharmaceuticals PR PD SD CR Percent change from baseline (%) Months Apr 14, 2022 data cutoff. RANO PD = ≥+25% change from baseline; RANO SD = <+24% to > -50% change from baseline;

  35. Slide 35: Tovorafenib Safety Data For the First Enrolled Patients

    Tovorafenib (DAY101) Safety Data For the First 25 Enrolled Patients (TEAEs ≥25% Any Grade) Day One Biopharmaceuticals Preferred term, n (%) Treatment-emergent AEs Treatment-related AEs Any grade Grade ≥3 Any grade Grade ≥3 Blood creatine phosphokinase increased 20 (80) 2 (8) 18 (72) 2 (8) Hair color

  36. Slide 36: Key Takeaways

    Key Takeaways Day One Biopharmaceuticals Encouraging initial efficacy data from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusion or BRAF V600 mutation, for whom there is no standard-of-care and no approved agents for the majority of patients 64% ORR and 91% cl

  37. Slide 37: Case Study: Tovorafenib in KIAA1549-BRAF Fusion Optic Pathway Glioma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma Day One Biopharmaceuticals Apr 14, 2022 data cutoff. Tovorafenib is an investigational agent. Safety and efficacy have not been established by any health authority. PR (-58%) and improvement in vision reported

  38. Slide 38: Case Study: Tovorafenib in Posterior Fossa Pilocytic Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma Day One Biopharmaceuticals Apr 14, 2022 data cutoff. Tovorafenib is an investigational agent. Safety and efficacy have not been established by any health authority. Baseline After 6 cycles Afte

  39. Slide 39: Case Study: Tovorafenib in BRAF V600E Deep Midline Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma Day One Biopharmaceuticals Apr 14, 2022 data cutoff. Tovorafenib is an investigational agent. Safety and efficacy have not been established by any health authority. Baseline After 6 cycles After 3 cycles Tum

  40. Slide 40: Results from Independent Radiology Review of PNOC014

    Results from Independent Radiology Review of PNOC014 Day One Biopharmaceuticals RAPNO: Response assessment for pediatric neuro-oncology (exploratory) RANO-HGG: Response assessment for neuro-oncology-high grade glioma Volumetric image analysis (exploratory) Best response from baseline Date of data cu

  41. Slide 41: Rapid, Deep and Durable Responses in PNOC014

    Multiple Rapid, Deep and Durable Responses Observed following Initiation of Tovorafenib (DAY101) Treatment of pLGG Patients in PNOC014 Day One Biopharmaceuticals Date of data cutoff: 02 JAN 2020 Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020 Fangusaro J et al. Lancet Oncol 2019

  42. Slide 42: Drug-related Adverse Events for Tovorafenib in PNOC014

    Drug-related Adverse Events Observed for Tovorafenib (DAY101) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Day One Biopharmaceuticals Date of DAY101 data cutoff: 02 JAN 2020; Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020; Fangusaro J et al. Lancet Oncol 2019 Toxicitie

Day One Biopharmaceuticals — Q1 2023 Earnings Presentation on 6ix